Business · 22/10/20261 min read
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
Summary
Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate Series C Preferred Stock private placement with existing long-term shareholders strengthen...
Original source language: PR Newswire — Global News ReleasesOpen original release →